COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution
- PMID: 32246966
- PMCID: PMC7118699
- DOI: 10.1016/j.jaad.2020.03.079
COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution
Comment in
-
Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".J Am Acad Dermatol. 2020 Jun;82(6):e215. doi: 10.1016/j.jaad.2020.03.103. Epub 2020 Apr 10. J Am Acad Dermatol. 2020. PMID: 32283232 Free PMC article. No abstract available.
Comment on
-
Should biologics for psoriasis be interrupted in the era of COVID-19?J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19. J Am Acad Dermatol. 2020. PMID: 32199889 Free PMC article. No abstract available.
References
-
- Florence A.L. Is thalidomide to blame? Br Med J. 1960;2(5217):1954.
-
- Uslu U., Heppt F., Sticherling M. Secondary syphilis infection under treatment with ustekinumab. Clin Exp Dermatol. 2017;42(7):836–838. - PubMed
-
- Kansal N.K. Syphilis screening before initiation of immunosuppressive and biologic therapy for psoriasis and psoriatic arthritis. Clin Exp Dermatol. 2018;43(7):831. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical